$-0.15 EPS Expected for Adamis Pharmaceuticals Corporation (ADMP)

March 1, 2018 - By Winifred Garcia

 $ 0.15 EPS Expected for Adamis Pharmaceuticals Corporation (ADMP)

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.15 EPS on March, 29. The stock increased 7.88% or $0.24 during the last trading session, reaching $3.24. About 1.10 million shares traded or 43.05% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 1, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Monday, August 21. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Tuesday, September 12 by Raymond James. The firm has “Buy” rating by Maxim Group given on Monday, June 12. Maxim Group maintained the stock with “Buy” rating in Thursday, July 21 report. The rating was maintained by Raymond James on Monday, December 4 with “Buy”. Maxim Group initiated the shares of ADMP in report on Tuesday, December 1 with “Buy” rating.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $108.05 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Marketwatch.com which released: “You still can’t buy this EpiPen competitor, eight months later” on February 27, 2018, also Globenewswire.com with their article: “Adamis Pharmaceuticals Updates Symjepi Commercialization Plans” published on February 23, 2018, Seekingalpha.com published: “Adamis Pharmaceuticals: Elucidating The Potential Commercial Partnership For …” on February 25, 2018. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Seekingalpha.com and their article: “What Happened To Adamis?” published on February 16, 2018 as well as Globenewswire.com‘s news article titled: “Adamis Pharmaceuticals Announces FDA Acceptance for Review for the …” with publication date: February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.